







































BDP = beclomethasone dipropionate; GR = glucocorticoid receptor; IFN = interferon; IL = interleukin; Kd = dissociation constant; MDI = metered-
dose inhalers; NA = nocturnal asthma; NNA = non-nocturnal asthma.
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Introduction
Asthma is a complex, chronic inflammatory lung disease
that is characterized by epithelial shedding, airway smooth
muscle hypertrophy and hyperplasia, overproduction of
mucus, and airway inflammation. The pathophysiology of
asthma has traditionally been attributed to an inflammatory
process that occurs predominantly in the large airways [1].
Early studies, conducted over 100 years ago, used
autopsy specimens to study the macroscopic morphologi-
cal and histological changes that occur within the large
asthmatic airways [1]. Those studies clearly showed that
asthma involves structural airway changes, including
increased size and amount of airway smooth muscle,
thickened basement membrane, mucus hypersecretion
and oedema in the airway wall.
The application of fibreoptic bronchoscopy in asthma has
enabled us to obtain small human endobronchial biopsies
from the large airways. This, together with the development
of molecular biology technologies (i.e. immunocytochem-
istry and in situ hybridization), has advanced our under-
standing of the pathogenesis of bronchial asthma [2,3].
Studies using surgically resected lung tissue [4–6],
autopsy lung specimens [7–9] and transbronchial biop-
sies [10,11] indicated that similar but more severe inflam-
matory and structural changes also occur in the small
airways [8,12,13] and in lung parenchyma [10] of asth-
matic persons. These findings may be extremely important,
because the total volume and the combined surface area
of the small airways are much greater than the surface
area of the large airways [14]. Currently, the therapeutic
challenge is to develop better inhalation technologies in
order to improve delivery of anti-inflammatory agents to the
lung periphery. The present review evaluates the physio-
logical and the pathological evidence presented to date
that outlines the contribution of the small airways to the
pathophysiology of asthma.
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Abstract
Asthma was originally described as an inflammatory disease that predominantly involves the central
airways. Pathological and physiological evidence reported during the past few years suggests that the
inflammatory process extends beyond the central airways to the peripheral airways and the lung
parenchyma. The small airways are capable of producing T-helper-2 cytokines, as well as chemokines,
and they have recently been recognized as a predominant site of airflow obstruction in asthmatic
persons. The inflammation at this distal site has been described as more severe than large airway
inflammation. These findings are of great clinical significance, and highlight the need to consider the
peripheral airways as a target in any therapeutic strategy for treatment of asthma.
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Physiological evidence
Most of our knowledge of lung function in asthmatic
persons comes from spirometric and plethysmographic
measurements made during bronchoprovocation, and
these are dominated by large airway responsiveness.
Because the volume and surface area of the lungs
increases with increasing airway generations, the contribu-
tion of peripheral resistance to the total lung resistance
was originally believed to be minimal [14]. Research con-
ducted over three decades ago, using a retrograde
catheter technique in animal models [15,16], demon-
strated that the small airways are pathways of small resis-
tance, contributing less than 10% of the total resistance
to airflow in the lung. Hence, Mead et al. [17] originally
described the small airways as the ‘quiet zone’ of the
lungs in 1970.
Since then, more sophisticated frequency-dependent
measurements of small airways function have been devel-
oped. Invasive studies in mongrel dogs using alveolar cap-
sules [18–20] or the forced oscillation technique [21,22]
have demonstrated that both airway and parenchymal
compartments contribute to airway hyper-responsiveness.
Methacholine-induced increase in parenchymal resistance
has also been reported in New Zealand white rabbits
[23,24], guinea pigs [25] and rats [19,26,27].
Invasive studies were carried out by Ohrui et al. [28] in
patients with asymptomatic asthma using a catheter-tipped
micromanometer wedged into the lower lobe of the
bronchus in order to partition central and peripheral airway
resistance. Those investigators constructed separate
dose/response curves in vivo, and showed a dose-depen-
dent increase in both central and peripheral airway resis-
tance in response to inhaled methacholine in all persons
studied. They proposed that inflammation-induced structural
changes in the small airways might be responsible. Van Bra-
bandt et al. [29] showed that the peripheral resistance con-
tributes between 50 and 90% of the total resistance in
normal lungs, as well as in the lungs of patients with chronic
obstructive lung disease. Those investigators concluded
that the contribution of the small airways to the total lung
resistance has thus far been grossly underestimated, and
that the physiological outcome is largely dependent on the
frequency used to measure peripheral lung mechanics. This
is because at high-frequency, low-amplitude oscillations the
contribution of the small airways to the total lung resistance
is minimized, whereas at low-frequency, high-amplitude
oscillations their contribution is maximized.
More recently peripheral airways, including lung tissue,
have been recognized as a predominant site of airflow
obstruction in asthmatic persons [30–32]. Wagner et al.
[33] showed that, in mild asthmatic persons with normal
spirometry, peripheral airway resistance was increased up
to sevenfold when compared with control individuals, and
these measurements correlated with responsiveness to
methacholine. In addition, computational analyses based
on quantitative histology [34,35] have shown the peripheral
airways to account for the majority of airway hyper-respon-
siveness among asthmatic persons [34,35]. Noninvasive
methodologies for separating airway and parenchymal
mechanics have been developed using the low-frequency
forced oscillation technique in animals [36] and in humans
[37,38]. With this technique, Hall et al. [39] demonstrated
that inhaled methacholine alters both airway and parenchy-
mal mechanics in infants, and that infants with a history of
wheeze have significantly increased parenchymal
responses to methacholine when compared with control
children. These studies further consolidate the contribution
of the small airways to the total lung resistance.
Pathological evidence
Bronchoscopic studies have shown that bronchial asthma
is characterized by infiltration of central airways with
inflammatory cells and an upregulation of T-helper-2-type
cytokines. A large proportion of information on the role of
peripheral airways in the pathophysiology of asthma came
from autopsy studies [7,8,40], because bronchoscopic
sampling was largely limited to proximal airway sites only.
Those studies showed that the entire length of the airway
is involved in asthma [35,41–43]. Carroll et al. [7] exam-
ined the distribution of inflammatory cells throughout the
bronchial tree both of fatal and of nonfatal cases of
asthma, and demonstrated increased numbers of lympho-
cytes and eosinophils that were uniformly distributed
throughout the large and small airways of mild and severe
asthmatic persons as compared with control cases.
Similar infiltration of T cells, macrophages and eosinophils
into the proximal and distal lung tissues has also been
reported in rare cases of sudden asthma death (dying
within one hour of onset of symptoms) [8] and in soybean
dust-induced asthma [13].
Using resected lung specimens from asthmatic and
nonasthmatic patients who underwent thoracic surgery,
we evaluated the inflammatory process throughout the
entire length of the airways [4]. Our results have shown
increased numbers of T cells (CD3+), total eosinophils
(major basic protein positive) and activated eosinophils
(EG2 positive) in both small (<2 mm internal diameter)
and large (>2 mm internal diameter) airways from asth-
matic patients when compared with those of control indi-
viduals (Figs 1 and 2). Comparing the large and small
airways directly, a greater number of activated eosinophils
(EG2 positive) was seen in airways with an internal diame-
ter of less than 2 mm (Fig. 3), suggesting that a similar but
more severe inflammatory process is present in the periph-
eral airways [44].
In the same cohort of patients, we also showed increased







































asthmatic persons as compared with nonasthmatic control
individuals (Fig. 4) [5]. More importantly, the expression of
IL-5 mRNA was increased in the small airways compared
with the large airways (Fig. 4) [5]. Numbers of cells
expressing IL-2 and IFN-γ mRNA were not elevated in
those subjects when compared with the control individu-
als. In addition, using simultaneous in situ hybridization
and immunocytochemistry, we were able to demonstrate
that 85% of the IL-5 mRNA-positive cells in the small
airways were T cells (CD3+), which is similar to the pro-
portion found in the large airways (81%) [5]. Recently,
increased expression of eotaxin and monocyte chemotac-
tic protein-4 mRNA has been reported in the epithelial cell
layer (Fig. 5) and in the airway wall of small airways of
asthmatic persons as compared with nonasthmatic control
individuals [6]. In that study, the number of chemokine-
positive cells correlated with the number of major basic
protein-positive eosinophils within the small airways [6].
The use of lung sections allows examination of the smooth
muscle cells. Haley et al. [45] evaluated the distribution of
CD45+ cells within the subepithelial regions of the airway
wall. They showed that the small asthmatic airways had
the majority of their inflammatory cells (CD45+ leukocytes
and eosinophils) in the ‘outer’ airway wall region, whereas
the greatest density of eosinophils in the large asthmatic
airways was in the ‘inner’ airway wall regions (with ‘outer’
being defined as the area between the smooth muscle
and the alveolar attachments, and ‘inner’ being defined as
the area between the basement membrane and the
smooth muscle). In addition, the small asthmatic airways
showed a greater number of CD45+ cells and eosinophils
in the ‘outer’ compared with the ‘inner’ airway wall region.
These differences highlight the regional variations in
inflammatory cell distribution within the asthmatic airway
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Figure 1
Immunocytochemical identification of (a) T cells (CD3) and (b) major
basic protein-positive eosinophils in airways that are greater than 2 mm
in diameter from patients with asthma. (c) Major basic protein
immunostaining of an airway greater than 2 mm in diameter from a
nonasthmatic person. (d) EG2-positive cells (activated eosinophils) in
an airway less than 2 mm in diameter. (e) T-cell immunostaining in
asthmatic airways that are less than 2 mm in diameter. (f) Eosinophil
major basic protein immunostaining in lung parenchyma tissue from
asthmatic patient. Adapted from Hamid et al. [4]. 
Figure 2
Immunocytochemical identification of T cells (CD3), total eosinophils
(major basic protein; MBP), activated eosinophils (EG2) and mast cells
(tryptase) in airways less than 2 mm in diameter (top) and in airways
greater than 2 mm in diameter (bottom) from patients with asthma.
Results given are average data from six (<2 mm) or 10 (>2 mm)
airways from four to six asthmatic patients and 13 (<2 mm) or 31
(>2 mm) airways from six to 10 control individuals. *P < 0.05, 
***P < 0.001 versus nonasthmatic, control individuals. Pi, internal
perimeter. Adapted from Hamid et al. [4].wall, and these differences appear to be disease specific
because such variations are not observed in cystic fibrosis
patients [45]. The different regional organization of inflam-
matory cells throughout the tracheobronchial tree may be
attributed to the differences in mechanisms of inflamma-
tory cell recruitment and/or differences in chemokine and
cytokine production between these regions. Haley et al.
[45] proposed that the smooth muscle layer of the small
airways may be a site of chemokine production.
In persons who die from asthma, inflammation extends
well beyond the airway smooth muscle and is still signifi-
cant around the pulmonary arterioles [46]. Kraft et al. [10]
showed that significant alveolar inflammation is present in
patients with nocturnal asthma (NA), which is not the case
in those with non-nocturnal asthma (NNA), suggesting
that alveolar tissue inflammation could also be important in
the pathogenesis of asthma. In those studies both proxi-
mal airway endobronchial and distal alveolar tissue trans-
bronchial biopsies were performed in each patient at
4.00 p.m. and at 4.00 a.m. Patients with NA demonstrated
increased numbers of eosinophils per lung volume in lung
parenchyma at 4.00 a.m. as compared with patients
without NA, and the NA group had a greater number of
eosinophils and macrophages in alveolar tissue at
4.00 a.m. than at 4.00 p.m. Moreover, in NA patients, only
alveolar (and not central airway) eosinophilia correlated
with overnight reduction in lung function [10].
In their most recently reported data, those investigators
showed increased numbers of CD4+ cells in the alveolar
tissue of NA patients at 4.00 a.m. when compared with the
NNA group [11,47]. Although the numbers of CD4+ cells
in the endobronchial lamina propria were higher than in the
alveolar tissue, only alveolar tissue CD4+ lymphocytes cor-
related with the predicted lung function (forced expiratory
volume in one second) at 4.00 a.m. (r = –0.68) and with
the number of activated alveolar eosinophils (EG2 positive;
r = 0.66) [11]. In this same cohort of patients, NA was
associated with reduced glucocorticoid receptor (GR)-
binding affinity (indicated by an increased Kd), reduced
proliferation of peripheral blood mononuclear cells and
decreased responsiveness to steroids at 4.00 a.m. com-
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Figure 3
Immunocytochemical identification of T cells (CD3), total eosinophils
(major basic protein; MBP), activated eosinophils (EG2) and mast cells
(tryptase) in airways less than 2 mm (black) and greater than 2 mm
(white) in diameter from patients with asthma. For airways that are less
than 2 mm in diameter, results are expressed as the mean of six
airways from four patients with asthma. For airways that are greater
than 2 mm in diameter, results are expressed as the mean of 10
airways from six patients with asthma. *P < 0.05 versus airways 
>2 mm Pi. Pi, internal perimeter. Adapted from Hamid et al. [4].
Figure 4
IL-4 and IL-5 mRNA expression in small (<2 mm in diameter) and large
(<2 mm in diameter) airways of asthmatic patients and control
individuals. For airways that are less than 2 mm in diameter, results are
expressed as the mean of 10 airways from four asthmatic patients and
14 airways from 10 control individuals. For airways that are greater
than 2 mm in diameter, results are expressed as the mean of 10
airways from six asthmatic patients and 10 airways from 10 control
individuals. *P < 0.05 versus control. Pi, internal perimeter. 
Adapted from Minshall et al. [5].pared with NNA patients [48]. These studies demonstrate
that the increased numbers of CD4+ cells in alveolar tissue
in NA patients, as well as the reduced GR-binding affinity
and reduced steroid responsiveness, may be responsible
for orchestrating eosinophil influx and exacerbations of
symptoms in these patients [11,48].
One of the mechanisms that may be responsible for this
phenomenon is an upregulation of GR-β, which has previ-
ously been reported in steroid-insensitive persons with
severe asthma [9]. Christodoulopoulos et al. [9] have
characterized the expression of GR-β within peripheral
airways in fatal asthma. They showed that the main cells
that expressed GR-β were CD3+ T lymphocytes and, to a
lesser extent, eosinophils, neutrophils and macrophages
[9]. Those results suggest that the increased number of
GR-β-positive cells in the small airways in fatal asthma
may be associated with steroid insensitivity, contributing
to asthma mortality.
Similar small airway inflammation has been reported in
severe symptomatic, steroid-dependent asthmatic
persons. Using endobronchial and transbronchial biop-
sies, Wenzel et al. [49] reported persistent proximal and
distal airway inflammation. Although the number of
eosinophils was similar between severe asthmatic persons
and normal control individuals, patients with severe
asthma had high numbers and percentages of neutrophils
in bronchoalveolar lavage, and endobronchial and trans-
bronchial biopsy specimens when compared with mild-to-
moderate asthmatic persons, despite aggressive
treatment with steroids. It has been speculated that the
inflammatory cell density in peripheral airways in severe
asthma may relate to the peripheral airway obstruction that
is characteristic of this disease. The small airway inflam-
mation may cause an uncoupling of the parenchyma and
airways due to the mechanical interdependence between
these two compartments, leading to changes in overall
lung mechanics in asthmatic persons. Those results have
therapeutic as well as diagnostic implications. 
Small airways as a therapeutic target in asthma
On the basis of the physiological and pathological evi-
dence presented in the present review, small or peripheral
airways and lung parenchyma are clearly implicated in the
pathogenesis of asthma. Because this is the ‘quiet’ zone,
however, damage in the small airways often goes un-
detected. What is unclear at present is whether inhaled
corticosteroids (the mainstay of asthma treatment) effec-
tively treat this compartment of the lung. Although inhaled
corticosteroids reduce airway inflammation in patients with
mild-to-moderate asthma [50,51], prolonged courses of
inhaled steroids do not normalize hyper-responsiveness
[52]. Furthermore, it was demonstrated in deposition
studies that most of the currently used inhaled cortico-
steroids are predominantly deposited in the central
airways and not in the lung periphery [53].
Metered-dose inhalers (MDIs), pressurized inhalers, or dry
powder inhalers are not very efficient at depositing med-
ication in the more peripheral airways of the lung. These
delivery systems typically deliver no more than 15% of the
inhaled dose to the lungs [54]. The challenge for the phar-
maceutical companies is to improve the technology of
aerosol delivery systems. This will ultimately allow delivery
of anti-inflammatory drugs to the peripheral and to the
central inflammatory sites with minimal oropharyngeal
deposition. Such technologies will thus enable us to treat










































Eotaxin (top) and monocyte chemotactic protein (MCP)-4 (bottom)
mRNA expression in the epithelium of small (<2 mm in diameter) and
large (<2 mm in diameter) airways of asthmatic patients and control
individuals. For airways that are less than 2 mm in diameter results are
expressed as the mean of 10 airways from four asthmatic patients and
14 airways from 10 controls. For airways that are greater than 2 mm in
diameter results are expressed as the mean of 10 airways from six
asthmatic patients and 10 airways from 10 control individuals. 
*P < 0.05, **P < 0.01 versus control. Pi, internal perimeter. 
Adapted from Taha et al. [6].Better lung deposition of the steroids may be achieved by
modification of propellants to produce finer and slower
moving aerosols. The latest development is the introduc-
tion of chlorofluorocarbon-free hydrofluoroalkane propel-
lants, which exhibit improved airway targeting when
compared with beclomethasone in chlorofluorocarbon
propellant [55–57]. Equivalent control of the disease and
improvement in lung function have been reported, and
studies have shown that this new formulation delivers
extra-fine particles (only 1.1 µm in diameter) [56,58].
Leach  et al. [55] have directly compared the steroid
airway targeting achieved using the novel hydrofluo-
roalkane MDI with that achieved with the conventional
chlorofluorocarbon MDI. By radiolabelling beclometha-
sone dipropionate (BDP), they demonstrated that hydro-
fluoroalkane propellant deposits 55–60% of BDP into the
lungs and 29–30% into the oropharynx. Using the chloro-
fluorocarbon propellant, however, only 4–7% of BDP was
deposited in the lungs and the remainder into the
oropharynx. With hydrofluoroalkane-BDP, those investigators
were able to demonstrate equivalent control of the disease
at half the daily dose required for chlorofluorocarbon-BDP. In
addition, Marshall et al. [59] have demonstrated that alveolar
deposition with inhaled hydrofluoroalkane-BDP is able to
inhibit lipopolysaccharide-induced production of tumour
necrosis factor-α by human alveolar macrophages cul-
tured ex vivo, suggesting that steroid distribution to the
alveoli might be beneficial for the treatment of asthma.
These radiolabelled drug deposition studies must be inter-
preted with caution, however, because the labelling
process itself may alter the distribution properties of the
inhaled steroid particles.
Conclusion
There is accumulating evidence to suggest that airway
inflammation occurs in all parts of the airway. Although the
clinical significance of small airways in asthma is not yet
known, it is possible that poorly controlled inflammation in
peripheral airways, which are not penetrated by conven-
tional inhaled steroids, may contribute to accelerated
decline in lung function and airway remodelling — the
hallmarks of asthma. The introduction of high-resolution
computed tomography allows assessment of the morpho-
logical changes (resulting from air trapping and regional
hyperinflation) in the small airways that are associated with
dysfunction too subtle to be identified with lung function
testing alone [60]. This novel, noninvasive imaging tech-
nique may prove to be important not only in the diagnosis
of small airway inflammation, but also in helping us move
toward a better understanding of the role of the small
airways in the pathogenesis of allergic asthma.
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